Slade awarded agreement to supply chemotherapy to South Australia public hospitals

Slade Health has been awarded the SA Health contract to provide chemotherapy compounding services across the state.  The transition of this service is now complete which includes supply to 23 South Australian metro and regional hospitals.

Slade currently operates four TGA-licenced manufacturing facilities in Victoria, New South Wales and Queensland, servicing over 200 clinics and hospitals nationally.  This includes the supply of compounded chemotherapy, antibiotics, sterile analgesics and like products.

David Slade, Slade Health CEO, said this is a welcome opportunity to extend on current services in South Australia.

“Slade Health is an organisation committed to exceptional patient care, delivery of quality products and an innovative approach to working with hospital pharmacy. The awarding of this tender recognises the scope of service we can deliver our clients. We look forward to working in partnership with SA Health to deliver this in the coming months.”

The agreement with South Australia cements Slade’s national presence in the sterile TGA compounding market, now servicing hospitals across six states and territories.